期刊文献+

首发偏执型精神分裂症血清NO/NOS水平的研究 被引量:1

A study of the serum level of nitric oxide and nitric oxide synthase in first-episode paranoid schizophrenia
暂未订购
导出
摘要 目的探讨首发偏执型精神分裂症血清一氧化氮/一氧化氮合成酶(NO/NOS)水平及与精神症状的关系。方法共收集首发偏执型精神分裂症患者26例(研究组),健康对照者30例(对照组),采用阳性与阴性症状量表(PANSS)评定患者的精神症状,同时检测血清NO/NOS水平。结果首发偏执型精神分裂症血清NO/NOS水平均显著高于健康对照组(t=2.08,P<0.05;t=2.72,P<0.05),血清NO/NOS水平与精神症状无显著相关性(P>0.05);血清NO水平与血清NOS水平两者存在显著正相关(r=0.41,P<0.05)。结论首发偏执型精神分裂症患者存在血清NO/NOS水平病理性增高。 Objective To explore the serum level of nitric oxide and nitric oxide synthase in first-- episode paranoid schizophrenia and their relationship with clinical symptoms. Methods The serum level of nitric oxide and nitric oxide synthase of 26 first--episode paranoid schizophrenia and 30 normal controls subjects were detected. Clinical symptoms were rated by Positive and Negative Syndromes Scale (PANSS). Results Both the serum level of nitric oxide and nitric oxide synthase of flrst--episode paranoid schizophrenia were higher than that of normal controls (P 〈 0.05) . Both the serum level of nitric oxide and nitric oxide synthase were not correlated with total or Subscale of PANSS (P 〉 0.05) . Conclusions There are high serum level of nitric oxide and nitric oxide synthase in first--episode paranoid schizophrenia.
出处 《神经疾病与精神卫生》 2007年第4期260-261,共2页 Journal of Neuroscience and Mental Health
基金 无锡市科委指导性项目(项目编号:CS055020)
关键词 偏执型精神分裂症 血清一氧化氮/一氧化氮合成酶水平 Episode paranoid schizophrenia Nitric oxide and nitric oxide synthase
  • 相关文献

参考文献7

二级参考文献46

  • 1汪辉,李胜利,钟杏圣,陈婉清,盘圣明,李敏伟,姚航平.精神分裂症免疫功能紊乱机理的研究[J].中国神经精神疾病杂志,1996,22(5):266-268. 被引量:11
  • 2Andreasen NC, Olsen S. Negative v positive schizophrenia:definition and validation. Arch Gen Psychiatry, 1982, 39:789-794.
  • 3Garthwaite J, Charles SL, Chess-Williams R. Endothelium-derived relaxing factor release onactivatlon of NMDA receptors suggests role as intrcellular messenger in the brain. Nature,1998,226:385-388.
  • 4Iadecola C. Bright and dark sides of nitric oxide in ischemic brain injury. Trends Neurosci. 1997.20;132-139.
  • 5Garthwaite J,Charles SL,Cheess Williams R.Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intracellular messenger in the brain.Nature,1988,336:385
  • 6Bujas-Bobanovic M,Robertson HA,Dursun SM.Effects of nitric oxide synthase inhibitor N(G)-nitro-L-arginine methyl ester-induced effects in rats.Eur J Pharmacol,2000,409:57
  • 7Deutsch SI,Rosse RB,Schwartz BL,et al.Methylene blue adjuvant therapy schzophrenia.Clin Neuropharmacol,1997,20:357
  • 8Andreasen NC,Olsen S.Negative vs Positive schizophrenia:definition and validation.Arch Gen Psychiatry,1982,32(10):789
  • 9Ganguli R, Brar JS, Chengappa KN, et al. Autoimmunity in schizophrenia:a review of recent tindings. Psychiatry Res, 1992,44(2): 113.
  • 10Licino L, Seiby JP, Altemus M, et al. Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenia patients. Am J Psychiatry, 1993, 150(9): 1408.

共引文献10

同被引文献22

  • 1Brennand KJ, Landek-Salgado MA, Sawa A. Modeling heterogeneous patients with a clinical diagnosis of schizophrenia with induced pluripotent stem cells[J]. Bio psyc, 2014, 75(12): 936-944.
  • 2Gurovich IY, Schmukler AB, Storozhakova YA, et al. Depressive symptoms diagnosis and treatment of schizophrenia and schizophrenia spectrum disorders in Russian clinical practice [J]. Zhurnal nevrologii i psikhiatrii imcni S.S. Korsakova, 2013, 113 (11 Pt 2): 28-33.
  • 3Foussias G, Agid O, Fervaha G, et al. Negative symptoms of schizophrenia: clinical features, relevance to real world functioning and specificity versus other CNS disorders [J]. Eur neuropsy, 2014, 24 (5): 693-709.
  • 4Volavka J, Czobor P, Citrome L, et al. Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study[J]. CNS spectrums, 2012, 10(7): 1-8.
  • 5Xiao Y, Lui S, Deng W, et al. Altered Cortical Thickness Related to Clinical Severity But Not the Untreated Disease Duration in Schizophrenia[J]. Schizophrenia bull, 2013, 11 (3): 34-39.
  • 6Tarbox SI, Addington J, Cadenhead KS, et al. Functional development in clinical high risk youth: prediction of schizophrenia versus other psychotic disorders[J]. Psychiatry research, 2014, 215(1): 52-60.
  • 7Vaisanen J, Ihalainen J, Tanila H, et al. Effects of NMDA-receptor antagonist treatment on c-fos expression in rat brain areas implicated in schizophrenia[J]. Cellular mol neuro, 2004, 24(6): 769-780.
  • 8Zuo DY, Cao Y, Zhang L, et al. Effects of acute and chronic administration of MK-801 on c-Fos protein expression in mice brain regions implicated in schizophrenia with or without clozapine [J]. Prog Ncuro-psy, 2009, 33(2): 290-295.
  • 9Barak S, Weiner I. The M (1)/M (4) preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia [J]. Int J neuropsych, 2011, 14(9): 1233-1246.
  • 10Eyjolfsson EM, Brenner E, Kondziella D, et al. Repeated injection of MK801: an animal model of schizophrenia? [J]. Neurochem int, 2006, 48(6-7): 541-546.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部